Journal of Healthcare Engineering / 2021 / Article / Tab 1 / Review Article
Efficacy and Safety of Stem Cell Combination Therapy for Osteonecrosis of the Femoral Head: A Systematic Review and Meta-Analysis Table 1 Baseline characteristics of included RCTs.
Study Year Country Study type Diagnostic criteria Disease stage Patient Age (years) Sex ratio (M/F) Intervention/control Stem cell source Stem cell counts Hips Follow-up (years) Gangji [18 ] 2011 Belgium RCT ARCO I/II 19 42.2 ± 2.6 NA CD + cell therapy BMMSCs 92.6 ± 22.4 × 107 13 5 Sen [15 ] 2012 India RCT ARCO I/II 40 NA NA CD + cell therapy BMMSCs 5.0 × 108 26 2 Zhao [17 ] 2012 China RCT ARCO I/II 100 32.7 ± 10.5 27 : 23 CD + cell therapy BMMSCs 2.0 × 106 53 5 Rastogi [14 ] 2013 India RCT ARCO I/II/III 40 34.67 ± 7.02 5 : 2 CD + cell therapy BMMSCs 1.1 × 108 30 2 Ma [11 ] 2014 China RCT ARCO I/II/III 39 35.60 ± 8.05 15 : 6 CD + autologous bone graft with BBC BMMSCs 3.0 × 109 25 2 Mao [12 ] 2015 China RCT ARCO I/II/III 55 34.60 ± 11.50 17 : 13 Biomechanical support + cell therapy PBSCs 2.47 ± 0.5 × 109 48 3 Tabatabaee [16 ] 2015 Iran RCT ARCO I/II/III 18 31.0 ± 11.4 9 : 5 CD + cell therapy BMMSCs 5.0 ± 2.0 × 108 14 2 Pepke [13 ] 2016 Germany RCT ARCO II 24 44.3 ± 3.4 10 : 1 CD + cell therapy BMMSCs NA 11 2 Hauzeur [5 ] 2018 Belgium RCT ARCO III 38 48.0 ± 2.8 14 : 5 CD + cell therapy BMMSCs 19.45 ± 3.51 × 109 23 2 Hernigou [6 ] 2018 France RCT ARCO I/II 125 18–54 78 : 47 CD + cell therapy BMMSCs 9.0 ± 2.5 × 104 125 25
NA = not available; CD = core decompression; BBC = bone marrow buffy coat; BMMSCs = bone marrow mesenchymal stem cells; PBSCs = peripheral blood stem cells.
